CJ BIOSCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14,790 KRW | +3.14% |
|
+7.10% | -8.36% |
| Sales 2022 | 4.07B 2.94M 4.04M | Sales 2023 | 5.58B 4.03M 5.53M | Capitalization | 147B 106M 146M |
|---|---|---|---|---|---|
| Net income 2022 | -34.91B -25.21M -34.63M | Net income 2023 | -22.91B -16.54M -22.73M | EV / Sales 2022 | 36.8 x |
| Net cash position 2022 | 20.36B 14.7M 20.19M | Net cash position 2023 | 55.56B 40.12M 55.12M | EV / Sales 2023 | 16.4 x |
| P/E ratio 2022 |
-4.88
x | P/E ratio 2023 |
-4.99
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 49.48% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.14% | ||
| 1 week | +7.10% | ||
| Current month | -7.33% | ||
| 1 month | -7.33% | ||
| 3 months | +1.09% | ||
| 6 months | +12.73% | ||
| Current year | -8.36% |
1 week
13 850.00
14 790.00
1 month
13 290.0016 250.00
Current year
13 290.0017 500.00
1 year
12 410.0033 800.00
3 years
12 410.0073 000.00
5 years
12 410.0073 000.00
10 years
12 410.0073 000.00
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Sik Chun
CEO | Chief Executive Officer | 57 | 09-10-31 |
Joon-Woo Lee
DFI | Director of Finance/CFO | - | - |
Hyeon Kim
CTO | Chief Tech/Sci/R&D Officer | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong-Soo Jung
BRD | Director/Board Member | 54 | - |
Joon-Woo Lee
DFI | Director of Finance/CFO | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-29 | 14,790 | +3.14% | 8 731 |
| 24-04-29 | 14,340 | +1.70% | 6,278 |
| 24-04-26 | 14,100 | +0.21% | 5,412 |
| 24-04-25 | 14,070 | -0.64% | 14,197 |
| 24-04-24 | 14,160 | +1.22% | 6,270 |
End-of-day quote Korea S.E., April 29, 2024
More quotes
CJ Bioscience Inc, formerly ChunLab Inc, is a Korea-based company principally engaged in the provision of microbial bioinformatics platform and solutions. The Company mainly provides microbial bioinformatics analysis services and microbiome-based healthcare services through bioinformatics database and cloud analytics platform. The Company also develops microbiome therapies and infection diagnosis solutions.
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -8.36% | 94.99M | |
| +0.80% | 42.86B | |
| +13.37% | 42.74B | |
| +44.76% | 41.36B | |
| -6.20% | 27.68B | |
| +6.54% | 25.15B | |
| -23.54% | 18.63B | |
| +29.51% | 12.37B | |
| -2.98% | 11.92B | |
| +7.01% | 11.21B |
- Stock Market
- Equities
- A311690 Stock
